Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Treasury Shares (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Treasury Shares for 11 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 39.21% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2025, up 39.21% year-over-year, with the annual reading at $2.3 million for FY2025, 39.21% up from the prior year.
  • Treasury Shares hit $2.3 million in Q4 2025 for Voyager Therapeutics, down from $2.5 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $2.8 million in Q1 2025 to a low of $806379.0 in Q4 2021.
  • Historically, Treasury Shares has averaged $1.6 million across 5 years, with a median of $1.4 million in 2023.
  • Biggest five-year swings in Treasury Shares: skyrocketed 115.05% in 2021 and later crashed 31.7% in 2022.
  • Year by year, Treasury Shares stood at $806379.0 in 2021, then soared by 37.97% to $1.1 million in 2022, then rose by 23.22% to $1.4 million in 2023, then grew by 20.35% to $1.6 million in 2024, then soared by 39.21% to $2.3 million in 2025.
  • Business Quant data shows Treasury Shares for VYGR at $2.3 million in Q4 2025, $2.5 million in Q3 2025, and $2.7 million in Q2 2025.